EUVIMEDEUVIMED entdecken
Crossref

The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines

Huanhuan Lu, Jinbo Xiao, Jingdong Song, Yang Song, Hai Li, Hu Ren, Jichen Li, Ruyi Cong, Hangwen Li, Yi Fang, Dongmei Yan, Shuangli Zhu und 3 weitere

Journal of Medical Virology · 2025-02 · 97 (2)

DOI: 10.1002/jmv.70201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 08.02.2025. Verfasst von Huanhuan Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Institute for Viral Disease Control and Pr…. Hauptthemen laut MEDLINE: Vaccines, Virus-Like Particle, Enterovirus A, Human, Immunogenicity, Vaccine, Viral Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: World Health Organization, This study was supported by the National Key Research and Development Program of China (Project No. 2024YFC2310403)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, coxsackievirus A6 (CVA6) has surpassed enterovirus A71 to become the main pathogen causing severe Hand, Foot, and Mouth disease (HFMD) in China with a substantial disease burden. However, there is currently no commercial CVA6 vaccine. The D3a genotype of CVA6 is the predominant genotype in China. In this study, virus‐like particles (VLPs) and mRNA vaccines based on the CVA6 sub‐genotype D3a were successfully developed. The immunogenicity and protective effects of the VLP of CVA6 combined with Al(OH) 3 and CpG adjuvant indicated that VLP‐induced neutralizing antibodies against three CVA6 sub‐genotype (D2, D3a, and D3b) strains in Institute of Cancer Research (ICR) mice, and the combination of the two adjuvants enhanced cellular immunity. Passive immunization with serum from mice immunized with VLPs protected suckling mice against CVA6 lethal challenge in both antiserum transfer and maternal immunization experiments. The immunogenicity and protective effects of the mRNA vaccine of CVA6 indicate that it induces robust T‐cell immunity. T‐cell immunity was found to cross‐protect against coxsackievirus A10 infection in mice. This is the first trial of a CVA6 mRNA vaccine worldwide and the first comparison of the immunogenicity and protective effects of VLP and mRNA vaccines based on D3a CVA6. The study provides a theoretical basis for the development of enteroviruses vaccines and the formulation of immunization strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, Virus-Like ParticleEnterovirus A, HumanImmunogenicity, VaccineViral VaccinesCoxsackievirus InfectionsAnimalsAntibodies, NeutralizingAntibodies, ViralMiceFemaleMice, Inbred ICRmRNA VaccinesAdjuvants, ImmunologicGenotypeVaccines, SyntheticChinaHand, Foot and Mouth DiseaseDisease Models, AnimalAdjuvants, VaccineT-LymphocytesImmunity, Cellular

Stichwörter der Autor:innen

coxsackievirus A6immunogenicitymRNA vaccineprotective effectsvirus‐like particle

Substanzen

Antibodies, NeutralizingVaccines, Virus-Like ParticleAntibodies, ViralmRNA VaccinesViral VaccinesAdjuvants, ImmunologicVaccines, SyntheticAdjuvants, Vaccine

Autor:innen und Institutionen

  • National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155, C…
  • National Polio Laboratory, World Health Organization Polio Reference Laboratory for the Western Pacific Region, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevent…
  • National Health Commission Key Laboratory of Laboratory Biosafety, National Institute for Viral Disease Prevention and Control, Chinese Center for Disease Control and Prevention, No.155, Changbai Road, Changping Distric…
  • Stemirna Therapeutics, Shanghai, China.
  • Shanghai East Hospital, Tongji University, Shanghai, China.

ORCID-Profile: Yong Zhang

Förderung

  • World Health Organization
  • This study was supported by the National Key Research and Development Program of China (Project No. 2024YFC2310403).

Zitieren

APA

Lu, H., Xiao, J., Song, J., Song, Y., Li, H., Ren, H., Li, J., Cong, R., Li, H., Fang, Y., Yan, D., Zhu, S., Sun, Q., Liu, Y., & Zhang, Y. (2025). The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70201

Vancouver

Lu H, Xiao J, Song J, Song Y, Li H, Ren H, et al. The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70201

BibTeX
@article{Lu2025,
  author = {Lu, Huanhuan and Xiao, Jinbo and Song, Jingdong and Song, Yang and Li, Hai and Ren, Hu and Li, Jichen and Cong, Ruyi and Li, Hangwen and Fang, Yi and Yan, Dongmei and Zhu, Shuangli and Sun, Qiang and Liu, Ying and Zhang, Yong},
  title = {The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {2},
  doi = {10.1002/jmv.70201}
}
Kostenlos starten →